These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12727938)

  • 21. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
    Bulotta S; Celano M; Costante G; Russo D
    Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on molecular biology of thyroid cancers.
    Omur O; Baran Y
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signaling Pathways in Thyroid Cancer.
    Jin S; Yang YT; Bao W
    Vitam Horm; 2018; 106():501-515. PubMed ID: 29407446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapies: focus on a new strategy for gastrointestinal tumors.
    Nicolella D; Maione P; Gridelli C
    Crit Rev Oncol Hematol; 2003 Sep; 47(3):261-71. PubMed ID: 12962900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New therapeutic advances in the management of progressive thyroid cancer.
    Woyach JA; Shah MH
    Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
    Schlumberger M; Lacroix L; Russo D; Filetti S; Bidart JM
    Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):260-9. PubMed ID: 17315034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 131I therapy of thyroid cancer patients.
    Reiners C; Farahati J
    Q J Nucl Med; 1999 Dec; 43(4):324-35. PubMed ID: 10731783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
    Morgan MA; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving use of radioiodine therapy in differentiated thyroid cancer.
    Mayson SE; Yoo DC; Gopalakrishnan G
    Oncology; 2015; 88(4):247-56. PubMed ID: 25503797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging molecular therapies of advanced thyroid cancer.
    Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
    Mol Aspects Med; 2010 Apr; 31(2):215-26. PubMed ID: 20176050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary management of papillary carcinoma of the thyroid gland.
    Rosenbaum MA; McHenry CR
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):317-29. PubMed ID: 19275510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond.
    Bulotta S; Celano M; Costante G; Russo D
    Curr Opin Oncol; 2020 Jan; 32(1):13-19. PubMed ID: 31599772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standard and emerging therapeutic approaches for thyroid malignancies.
    Brown RL
    Semin Oncol; 2008 Jun; 35(3):298-308. PubMed ID: 18544444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
    Kurzrock R; Cortes J; Kantarjian H
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy for thyroid cancer: current status and future prospects.
    Spitzweg C; Morris JC
    Thyroid; 2004 Jun; 14(6):424-34. PubMed ID: 15242569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.